Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Fry

Showing results (301-310 of 305) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 305 results.
Journal of Medicinal Chemistry|June 9, 2006
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activityBruce G Szczepankiewicz, Christi Kosogof, Lissa T J Nelson, et al.
British Journal of Pharmacology|May 6, 2008
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1C J Langmead, N E Austin, C L Branch, et al.
Journal of Medicinal Chemistry|June 9, 2006
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitorsZhonghua Pei, Xiaofeng Li, Kenton Longenecker, et al.
ACS Chemical Biology|November 25, 2010
Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinasesKenneth M Comess, Chaohong Sun, Cele Abad-Zapatero, et al.
Frontiers in Immunology|October 2, 2025
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCTSinead Delany-Moretlwe, Hakim-Moulay Dehbi, Izukanji Sikazwe, et al.
Pageof 31

Showing results (301-310 of 305) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 305 results.
Journal of Medicinal Chemistry|June 9, 2006
Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activityBruce G Szczepankiewicz, Christi Kosogof, Lissa T J Nelson, et al.
British Journal of Pharmacology|May 6, 2008
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1C J Langmead, N E Austin, C L Branch, et al.
Journal of Medicinal Chemistry|June 9, 2006
Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitorsZhonghua Pei, Xiaofeng Li, Kenton Longenecker, et al.
ACS Chemical Biology|November 25, 2010
Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinasesKenneth M Comess, Chaohong Sun, Cele Abad-Zapatero, et al.
Frontiers in Immunology|October 2, 2025
No evidence of MMR induced trained immunity to prevent SARS COV2: results from a multi-centre RCTSinead Delany-Moretlwe, Hakim-Moulay Dehbi, Izukanji Sikazwe, et al.
Pageof 31